Treatment options for patients with moderately to severely active Crohn's disease have expanded in the past decade, with ...

In a major advance for patients with Crohn's disease, a new study led by researchers at Mount Sinai Health System found that ...

In a major advance for patients with Crohn's disease, a new study led by researchers at Mount Sinai Health System found ...

Peter Mac researchers have discovered a powerful new drug combination that could offer hope to children and adults with ...

Dr. Zuraw led clinical development of telitacicept across MG, Sjögren’s, SLE, and RA at RemeGen, resulting in multiple ...

Johnson & Johnson (NYSE:JNJ) on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year ...

Now, after setting an innovative medicines sales record in the year’s second quarter, it appears J&J’s confidence was well placed.

A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals ...

Guselkumab and risankizumab for psoriasis have the highest rates of drug survival among biologics measured and a comparable safety profile.

A new study published in the Journal of American Medical Association showed that Guselkumab was highly effective and durable ...

As summer began and temperatures rose in June, so too did TV ad spending for Novo Nordisk’s Wegovy. | As summer began and temperatures rose in June, so too did TV ad spending for Novo Nordisk’s Wegovy ...

Discover a study that demonstrates the effectiveness of guselkumab in treating scalp psoriasis, offering significant symptom ...